Abstract
Glycated hemoglobin is currently the gold standard for assessment of long-term glycemic control and response to medical treatment in patients with diabetes. Glycated hemoglobin, however, does not address fluctuations in blood glucose. Glycemic variability (GV) refers to fluctuations in blood glucose levels. Recent clinical data indicate that GV is associated with increased risk of hypoglycemia, microvascular and macrovascular complications, and mortality in patients with diabetes, independently of glycated hemoglobin level. The use of continuous glucose monitoring devices has markedly improved the assessment of GV in clinical practice and facilitated the assessment of GV as well as hypoglycemia and hyperglycemia events in patients with diabetes. We review current concepts on the definition and assessment of GV and its association with cardiovascular complications in patients with type 2 diabetes.
Subject
Endocrinology, Diabetes and Metabolism
Reference55 articles.
1. International Diabetes Federation . IDF diabetes atlas teB, Belgium, 2019. Available: https://www.diabetesatlas.org
2. Cardiovascular safety of liraglutide for the treatment of type 2 diabetes;Chudleigh;Expert Opin Drug Saf,2017
3. The Lancet Commission on diabetes: using data to transform diabetes care and patient lives;Chan;Lancet,2021
4. Macrovascular complications in patients with diabetes and prediabetes;Huang;Biomed Res Int,2017
5. Mortality and causes of death in the who multinational study of vascular disease in diabetes;Morrish;Diabetologia,2001
Cited by
74 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献